Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2019

May 13, 2019

SELL
$3.63 - $6.06 $93,889 - $156,741
-25,865 Closed
0 $0
Q1 2018

May 04, 2018

SELL
$7.1 - $11.56 $687,130 - $1.12 Million
-96,779 Reduced 78.91%
25,865 $291,000
Q3 2017

Nov 08, 2017

BUY
$4.93 - $8.93 $604,634 - $1.1 Million
122,644
122,644 $1 Million

Others Institutions Holding ADAP

About Adaptimmune Therapeutics PLC


  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $73.5M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track This Portfolio

Track Granite Investment Partners, LLC Portfolio

Follow Granite Investment Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Granite Investment Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Granite Investment Partners, LLC with notifications on news.